Small-scale trials aid device and trial design
This article was originally published in Clinica
Studies of only a few patients at a single clinical centre can be crucial when developing a new medical device, but, contrary to the views of some, they must conform with regulation. And, if they are to attain their objectives, they need careful planning.
You may also be interested in...
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.
AstraZeneca's research head admits that the half dose approach was a lucky mistake – but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.